

СПИСОК ЛИТЕРАТУРЫ

1. Бакулин И.Г., Жигалова Т.Н., Латария Э.Л., Сказываева Е.В., Скалинская М.И., Ситкин С.И., Попова Е.А. Опыт внедрения Федерального регистра пациентов с воспалительными заболеваниями кишечника в Санкт-Петербурге. Фарматека, 2017, 17: 56-59.
2. Бакулин И.Г., Скалинская М.И., Сказываева Е.В. Место месалазина в терапии язвенного колита. Медицинский совет, 2017, 15: 76-80.
3. Бакшт А.Е., Белобородова Э.И., Белобородова Е.В., Наумова Е.Л., Бурковская В.А. Копинг-стратегии больных хроническими воспалительными заболеваниями кишечника. Бюллетень сибирской медицины, 2013, 6(12): 99-102.
4. Белоусова Е.А., Морозова Н.А., Никитина Н.В. Инфликсимаб (ремикейд) в лечении рефрактерных форм болезни Крона. РМЖ, 2005, 7(1): 28-32.
5. Голышева С.В., Мешалкина Н.Ю., Григорьева Г.А. Качество жизни пациентов с язвенным колитом и болезнью Крона. Лечащий врач, 2010, 9: 85.
6. Захарова Н.В. Антибиотикоассоциированная диарея: патогенез, лечение. Врач, 2013, 1: 35-39.
7. Ивашкин В.Т., Шельгин Ю.А., Халиф И.Л., Белоусова Е.А. и др. Клинические рекомендации Российской гастроэнтерологической ассоциации и Ассоциации колопроктологов России по диагностике и лечению язвенного колита. Колопроктология, 2017, 1: 6-30.
8. Ивашкин В.Т., Шельгин Ю.А., Халиф И.Л., Белоусова Е.А. и др. Клинические рекомендации Российской гастроэнтерологической ассоциации и Ассоциации колопроктологов России по диагностике и лечению болезни Крона. Колопроктология, 2017, 2: 7-30.
9. Скалинская М.И., Бакулин И.Г., Сказываева Е.В., Жигалова Т.Н., Рындин К.Н., Соловьев М.В. Биологические препараты в терапии воспалительных заболеваний кишечника: реальность и перспективы. Фарматека, 2017, 17: 85-93.

10. Ananthakrishnan AN. Epidemiology and risk factors for IBD. *Nature Reviews Gastroenterology & Hepatology*, 2015, 12(4): 205-217.
11. Cho JH, Brant SR. Recent insights into the genetics of inflammatory bowel disease. *Gastroenterology*, 2011, 140: 1704-1712.
12. Chen JH, Andrews JM, Kariyawasam V, Moran N. IBD Sydney Organisation and the Australian Inflammatory Bowel Diseases Consensus Working Group. Review article: acute severe ulcerative colitis - evidence-based consensus statements. *Aliment. Pharmacol. Ther.*, 2016, 44(2): 127-144.
13. Colombel JF, Sands BE, Rutgeerts P, Sandborn W, Danese S, D'Haens G, Panaccione R, Loftus Jr EV, Sankoh S, Fox I, Parikh A, Milch C, Abhyankar B, Feagan BG. The safety of vedolizumab for ulcerative colitis and Crohn's disease. *Gut*, 2016; 0: 1-13.
14. Dignass A et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management. *J. Crohns Colitis.*, 2012, 6(10): 991-1030.
15. Dignass A, Stoyanov S, Dorofeyev AE et al. Once versus three times daily dosing of oral budesonide for active Crohn's disease: double-blind, double-dummy, randomised trial. *Journal of Crohns & Colitis*, 2014, 8(9): 970-980.
16. Doecke JD, Simms LA, Zhao ZZ et al. Genetic susceptibility in IBD: overlap between ulcerative Colitis and Crohn's disease. *Inflammatory Bowel Diseases*, 2013, 19(2): 240-245.
17. Eckburg PB, Relman DA. The role of microbes in Crohn's disease. *Clin. Infect. Dis.*, 2007, 44: 256-262.
18. Frank DN, Amand AL, Feldman RA, Boedeker EC, Harpaz N. Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. *Proceedings of the National Academy of Sciences*, 2007, 104(34): 13780-13785.
19. Feagan BG et al. Efficacy of Vedolizumab Induction and Maintenance Therapy in Patients With Ulcerative Colitis, Regardless of Prior Exposure to Tumor Necrosis Factor Antagonists *Clin. Gastroenterol. and Hepatol.* 2017; 15: 229-239.

20. Gracie DJ, Ford AC. IBS-like symptoms in patients with ulcerative colitis. *Clin. Exp. Gastroenterol.*, 2015, 8: 101-109.
21. Harbord M, Annesse V, Vavricka SR et al. The first European evidence-based consensus on extra-intestinal manifestations in inflammatory bowel disease. *J Crohns Colitis.*, 2016, 10: 239-254.
22. Hanauer S, Feagan B, Lichtenstein G et al. Maintenance Infliximab for Crohn's Disease: the ACCENT I Randomised Trial. *Lancet*, 2002, 359: 1541-1549.
23. Khor B, Gardet A, Xavier RJ. Genetics and pathogenesis of inflammatory bowel disease. *Nature*, 2011, 474: 307.
24. Lee D, Albenberg L, Compher C et al. Diet in the pathogenesis and treatment of inflammatory bowel diseases. *Gastroenterology*, 2015, 148(6): 1087-1106.
25. Loddo I, Romano C. Inflammatory bowel disease: genetics, epigenetics, and pathogenesis. *Frontiers in Immunology*, 2015, 6: 551.
26. Lowenberg M, de Boer NK, Hoentjen F. Golimumab for the treatment of ulcerative colitis. *Clin. Exp. Gastroenterol*, 2014, 7: 53-59.
27. Rutgeerts P. A Critical Assessment of new Therapies in Inflammatory Bowel Diseases. *J.Gastroenterol. Hepatol.*, 2002, 17: 177.
28. Ruiz Garcia V, Jobanputra P, Burls A et al. Certolizumab pegol Niti Goel and Sue Stephens. *MAbs*, 2010, 2(2): 137-147.
29. Sands BE et al. Efficacy of Vedolizumab Induction Therapy in Patients With Crohn's Disease Who Have Experienced Tumor Necrosis Factor Antagonist Failure or Are Tumor Necrosis Factor Antagonist Naïve. *Inflam. Bowel Dis.* 2017, 23: 97-106.
30. Seah D, De Cruz P. Review article: the practical management of acute severe ulcerative colitis. *Aliment. Pharmacol.Ther.*, 2016, 43(4): 482-513.
31. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. *N. Engl. J. Med.*, 1987, 317: 1625-1629.
32. Silverberg MS, Satsangi J, Ahmad T et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel

disease: Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. *Can J Gastroenterol*, 2005, 19(A): 5-36.

33. Subramanian V, Pollok RC, Kang JY, Kumar D. Systematic review of postoperative complications in patients with inflammatory bowel disease treated with immunomodulators. *Br. J. Surg.*, 2006, 93: 793-799.

34. Truelove SC et al. Cortisone in ulcerative colitis; final report on a therapeutic trial. *Br. Med. J.*, 1955, 2: 1041-1048.

35. Triantafyllidis J, Vagianos C, Papalois A. The Role of Enteral Nutrition in Patients with Inflammatory Bowel Disease: Current Aspects. *Biomed Res Int.*, 2015: 197167.

36. Tursi A, Allegretta L, Buccianti N et al. Effectiveness and Safety of Golimumab in Treating Outpatient Ulcerative Colitis: A Real-Life Prospective, Multicentre, Observational Study in Primary Inflammatory Bowel Diseases Centers. *J. Gastrointestin Liver Dis.*, 2017, 26(3): 239-244.

37. Yang Z, Wu Q, Wang F, Wu K, Fan D. Meta-analysis: effect of preoperative infliximab use on early postoperative complications in patients with ulcerative colitis undergoing abdominal surgery. *Aliment Pharmacol Ther*, 2012, 36(10): 922-928.

38. Zheng Yang, Xiao-Qing Ye, Yu-Zhen Zhu et al. Short-term effect and adverse events of adalimumab versus placebo in inducing remission for moderate-to-severe ulcerative colitis: a meta-analysis. *Int J Clin Exp Med.*, 2015, 8(1): 86-93.